Fig. 8
From: Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer
High expression of CD226 and KLRC4-KLRK1 results in a better prognosis in breast cancer. The survival probability differences between high and low CD226 expression in (A) stage II, (B) stage III, and (C) the luminal B subtype of breast cancer. The survival probability differences between high and low KLRC4-KLRK1 expression in (D) stage II, (E) stage III, and (F) the luminal B subtype of breast cancer. P < 0.05 in the log-rank test